Background-Recently, the association of a polymorphism in the gene coding for the anti-inflammatory cytokine interleukin-l receptor antagonist with ulcerative colitis has been reported. This was interpreted as a possible genetic predisposition for severity of the inflammatory response. Aims-To examine this polymorphism in a southern German population. Subjects-The study included 234 healthy controls, 57 patients with ulcerative colitis, including 31 patients with pancolitis, 44 first degree healthy relatives of patients with ulcerative colitis, and 65 patients with Crohn's disease. Methods-Genotypes were determined by a polymerase chain reaction amplification of the intron 2 fragment harbouring a variable number of tandem repeat nucleotide sequences. Amplification products were separated on a 2% agarose gel. Results-The allele frequency for allele 2 was 27% in healthy controls, 28% in Crohn's disease, and 21% in patients with ulcerative colitis. The same allele frequency (21%) was found in a subgroup of patients with ulcerative colitis affecting the whole colon. Thus for allele 2 as well as for all other alleles, genotypes, or carriage rates no significant differences were found compared with controls. All allele frequencies in the control population were similar to those in earlier studies.
Clear evidence exists for a genetic predisposition to inflammatory bowel disease. The prevalence of ulcerative colitis and Crohn's disease is different between distinct ethnic groups.' Relatives of patients with ulcerative colitis and Crohn's disease have an increased risk for developing inflammatory bowel disease.2 Furthermore, twin studies have provided evidence for genetic factors, particularly in Crohn's disease.6 Genetic markers for inflammatory bowel disease have been identified in the major histocompatibility complex.7
An association between the HLA-DR2 allele and ulcerative colitis has been described.8 In Crohn's disease the haplotype HLA-DRI DQ,5 was found with increased frequency.8
Interleukin-I is a cytokine with potent proinflammatory properties and plays a central part in various inflammatory diseases.9'-It is the only cytokine for which a physiological antagonist -interleukin-1 receptor antagonist -has been identified. '2-17 The results of a study by Casini et al point to a role for the balance between the proinflammatory cytokine interleukin-1 and its receptor antagonist in inflammatory bowel disease. '8 A polymorphism in the gene coding for interleukin-1 receptor antagonist has been described'9 (Table I ). In the second intron of this gene five alleles are defined by different numbers (two to six) of repeats of a 86 bp segment (variable number of tandem repeats). Recently, an association between this polymorphism and ulcerative colitis has been described.20 An increase in the frequency of allele 2 was reported in patients with ulcerative colitis, especially in those with involvement of the entire colon. This was the first observed association of ulcerative colitis with a gene outside the major histocompatibility complex. There are interindividually stable differences in the production of certain cytokines. receptor antagonist was noted. Allele 2 of the polymorphism was associated with an increased production of interleukin-1 receptor antagonist protein in healthy humans when mononuclear cells were stimulated with GM-CSF. 23 It was speculated that a genetic influence -caused by the polymorphism in the interleukin-I receptor antagonist gene -on the production of interleukin-1 receptor antagonist could contribute to the mechanism of inflammatory disease. In the present study we attempted to confirm the recently described20 association of the polymorphism in the interleukin-1 receptor antagonist gene in a large southern German patient population with ulcerative colitis.
Methods

PATIENTS
The study comprised 234 unrelated healthy volunteers, 57 patients with ulcerative colitis, and 65 patients with Crohn's disease. Furthermore, 44 first degree relatives of patients with ulcerative colitis were studied. The diagnosis and extent of disease had been determined by radiological, endoscopic, and histological criteria (Table II) . Informed consent was obtained from all patients. Germany) contained 100 mM Tris-HCl at pH 8-3 (25°C) and 500 mM KC1. The final MgCl2 concentration in the PCR reaction was 3 mM. Dimethyl sulphoxide (DMSO; 2%; Sigma, Munich, Germany) was added. The reaction volume was 20 ,ul. The incubation parameters were: first denaturation at 94°C for three minutes followed by 94°C (one minute), 65°C (one minute), and 72°C (one minute) for two cycles, 94°C (one minute), 63°C (one minute), and 72°C (one minute) for two cycles and 94°C (one minute), 60°C (one minute), and 72°C (one minute) for 30 cycles. The final extension was carried out at 72°C for five minutes. The PCR product was separated by electrophoresis on a 2% agarose gel stained with ethidium bromide. A molecular ladder in steps of 123 bp ranging from 123 to 4182 bp (Gibco BRL, Berlin, Germany) was used to determine the size of the PCR products (Fig 1) .
STATISTICS
The allele frequencies and carriage rates were calculated from the numbers of genotypes. For statistical analyses the x2 test was performed on allele frequencies, and genotypes and carriage rates.
Results
In healthy controls (n=234) allele frequencies were 69% for allele 1, 27% for allele 2, and 4% for the sum of alleles 3, 4, and 5 (Table III) . patients with an involvement of the entire colon (Fig 3) . The allele frequencies, genotype frequencies, and carriage rates showed no significant differences in these subgroups of patients with ulcerative colitis compared with controls. Also in the first degree healthy relatives of patients with ulcerative colitis, allele and genotype frequencies were similar to controls (Table III) .
In patients with Crohn's disease the allele frequencies were 72% for allele 1 and 28% for allele 2 (Table III) 
